Long-term results after combined modality treatment for non-metastatic osteosarcoma

1999 ◽  
Vol 16 (4) ◽  
pp. 255-260 ◽  
Author(s):  
J Aparicio ◽  
A Segura ◽  
J Montalar ◽  
S Garcerá ◽  
A Oltra ◽  
...  
Keyword(s):  
Long Term Results ◽  
Combined Modality Treatment ◽  
Combined Modality ◽  
Metastatic Osteosarcoma

957 poster LONG TERM RESULTS FOR COMBINED MODALITY TREATMENT FOR ANAL CANCER

2011 ◽  
Vol 99 ◽  
pp. S365
Author(s):  
I. Oblak ◽  
P. Petric ◽  
A.L. Vodusek ◽  
V. Velenik ◽  
F. Anderluh ◽  
...  
Keyword(s):  
Anal Cancer ◽  
Long Term Results ◽  
Combined Modality Treatment ◽  
Combined Modality

Neutron and Neutron-Photon Therapy for Head and Neck Cancer

2015 ◽  
Vol 1084 ◽  
pp. 409-412
Author(s):  
Olga Gribova ◽  
Ludmila Musabaeva ◽  
Evgenij Choynzonov ◽  
Valerij Novikov
Keyword(s):  
Thyroid Gland ◽  
Long Term Results ◽  
Fast Neutrons ◽  
Salivary Gland Cancer ◽  
Combined Modality Treatment ◽  
Study Group ◽  
Combined Modality ◽  
Thyroid Gland Cancer ◽  
Radiotherapy Alone

The study group comprised 124 patients with salivary gland cancer and 46 patients with thyroid gland cancer who received the combined modality treatment and radiotherapy alone with the use of 6.3 MeV fast neutrons generated within U-120 cyclotron. The combined modality treatment and radiation therapy with the use of fast neutrons allow encouraging long-term results to be achieved for patients with salivary and thyroid gland cancers.

Long-term results of combined modality treatment with I-125 implantation for carcinoma of the pancreas

1992 ◽  
Vol 23 (2) ◽  
pp. 305-311 ◽  
Author(s):  
Mohammed Mohiuddin ◽  
Francis Rosato ◽  
Donna Barbot ◽  
Alan Schuricht ◽  
William Biermann ◽  
...  
Keyword(s):  
Long Term Results ◽  
Combined Modality Treatment ◽  
Carcinoma Of The Pancreas ◽  
Combined Modality

Complete pathologic response after combined-modality treatment for rectal cancer and long-term survivals: A meta-analysis.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 479-479 ◽  
Author(s):  
L. Zorcolo ◽  
A. S. Rosman ◽  
A. Restivo ◽  
M. Pisano ◽  
G. R. Nigri ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Meta Analysis ◽  
Neoadjuvant Chemoradiotherapy ◽  
Small Sample ◽  
Pathologic Response ◽  
Long Term Results ◽  
Combined Modality Treatment ◽  
Complete Pathologic Response ◽  
Combined Modality

479 Background: Recent literature suggests that a complete pathologic response (CPR) following neoadjuvant chemoradiotherapy (combined modality treatment, CMT) for rectal cancer is associated with improved survivals compared to partial or no response (NPR). However, previous reports have been limited by small sample size and single-institution design. To overcome these limitations, we performed a meta- analysis of studies evaluating the prognostic value of CPR. Methods: A systematic literature review was conducted to detect studies comparing long-term results of patients with CPR or NPR after CMT for rectal cancer. Variables were pooled only if evaluated by 3 or more studies. Both qualitative and quantitative data were pooled using a random-effects model. Study endpoints included rates of complete pathological response, local recurrence (LR), distant recurrence (DR), as well as 5-year overall (OS) and disease-free survival (DFS). Results: There were 13 studies suitable for the meta-analysis, that overall reported on outcomes of 2030 patient with rectal cancer treated with CMT. CPR was achieved in 332 patients (16.4%). CPR and NPR patients groups were similar with respect to age, male gender, tumor size, distance of tumor from the anus and pre- treatment stage (p > 0.3 for all comparisons). Median follow-up ranged from 23.5 to 46 months. CPR patients had lower rates of LR (0.7% vs. 2.6%; odds ratio [OR]=0.45, 95% CI 0.22–0.90), DR (5.3% vs. 24.1%; OR=0.15, 95% CI 0.07–0.31) and LR+DR (0.7% vs. 4.8%; OR=0.32, 95% CI 0.13–0.79). OS was 92.6% for CPR vs. 73.2% for NPR (OR=3.6, 95% CI 1.84–7.06), and DFS was 89.1% vs. 64.3% (OR=4.3, 95% CI 1.8-10.1). Conclusions: Our meta-analysis confirms that a CPR following CMT for rectal cancer is associated with an improved local and distal control as well enhanced OS and DFS. No significant financial relationships to disclose.

Combined-Modality Treatment and Selective Organ Preservation in Invasive Bladder Cancer: Long-Term Results

2002 ◽  
Vol 20 (14) ◽  
pp. 3061-3071 ◽  
Author(s):  
Claus Rödel ◽  
Gerhard G. Grabenbauer ◽  
Reinhard Kühn ◽  
Thomas Papadopoulos ◽  
Jürgen Dunst ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Early Stage ◽  
Long Term Results ◽  
Combined Modality Treatment ◽  
Disease Specific Survival ◽  
Bladder Preservation ◽  
Combined Modality ◽  
Disease Specific ◽  
Salvage Cystectomy

PURPOSE: To evaluate our long-term experience with combined modality treatment and selective bladder preservation and to identify factors that may predict treatment response, risk of relapse, and survival. PATIENTS AND METHODS: Between 1982 and 2000, 415 patients with bladder cancer (high-risk T1, n = 89; T2 to T4, n = 326) were treated with radiotherapy (RT; n = 126) or radiochemotherapy (RCT; n = 289) after transurethral resection (TUR) of the tumor. Six weeks after RT/RCT, response was evaluated by restaging-TUR. In case of complete response (CR), patients were observed at regular intervals. In case of persistent or recurrent invasive tumor, salvage-cystectomy was recommended. Median follow-up was 60 months (range, 6 to 199 months). RESULTS: CR was achieved in 72% of patients. Local control after CR without muscle-invasive relapse was maintained in 64% of patients at 10 years. Distant metastases were diagnosed in 98 patients with an actuarial rate of 35% at 10 years. Ten-year disease-specific survival was 42%, and more than 80% of survivors preserved their bladder. Early tumor stage and a complete TUR were the most important factors predicting CR and survival. RCT was more effective than RT alone in terms of CR and survival. Salvage cystectomy for local failure was associated with a 45% disease-specific survival rate at 10 years. Cystectomy because of a contracted bladder was restricted to 2% of patients. CONCLUSION: TUR with RCT is a reasonable option for patients seeking an alternative to radical cystectomy. Ideal candidates are those with early-stage and unifocal tumors, in whom a complete TUR is accomplished.

Long-Term Results of Combined-Modality Therapy in Resectable Non–Small-Cell Lung Cancer

2002 ◽  
Vol 20 (8) ◽  
pp. 1989-1995 ◽  
Author(s):  
Jocelyne Martin ◽  
Robert J. Ginsberg ◽  
Ennapadam S. Venkatraman ◽  
Manjit S. Bains ◽  
Robert J. Downey ◽  
...  
Keyword(s):  
Combined Modality Therapy ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Complete Resection ◽  
Small Cell ◽  
Long Term Results ◽  
Small Cell Lung ◽  
Combined Modality

PURPOSE: Assessment of long-term results of combined-modality therapy for resectable non–small-cell lung cancer is hampered by insufficient follow-up and small patient numbers. To evaluate this, we reviewed our collective experience. PATIENTS AND METHODS: This study was a retrospective chart review recording demographics, tumor stage, treatment, and outcome of consecutive patients undergoing surgery. Survival was analyzed by Kaplan-Meier, and prognostic factors were analyzed by log-rank and Cox regression. RESULTS: From January 1993 to December 1999, 470 patients were treated, with follow-up in 446: 27 stage I, 55 stage II, 316 stage III, 43 stage IV (solitary M1), and five uncertain. Chemotherapy was mitomycin/vinblastine/cisplatin (174 patients [39.0%]), carboplatin/paclitaxel (148 [33.2%]), and other combination (124 [27.8%]); 75 patients (16.8%) received induction radiation. Resection was complete in 77.4%, incomplete in 8.3%, attempted but with gross residual disease afterward in 1.8%, and not performed in 12.6%. Pathologic complete response occurred in 20 patients (4.5%). With median follow-up of 31.0 months for patients still alive, median and 3-year survival for pathologic stages 0, I, II, III, and IV were more than 90 months, 73%; 42 months, 52%; 23 months, 35%; 16 months, 28%; and 16 months, 23% (P < .001). In a multivariate analysis, age, complete resection, pathologic stage, and pneumonectomy, but not induction regimen, significantly influenced survival. CONCLUSION: Although pathologic complete response outside the protocol setting is low, survival of this large patient cohort is comparable to that of patients in published combined-modality trials. Survival is significantly influenced by patient age, complete resection, pathologic stage, and pneumonectomy. These results can help guide standard clinical practice and emphasize the need for novel induction regimens.

Involved node radiation therapy in the combined modality treatment for early-stage Hodgkin lymphoma: Analysis of relapse location and long-term outcome

2020 ◽  
Vol 150 ◽  
pp. 236-244
Author(s):  
Karin Nielsen ◽  
Maja Vestmoe Maraldo ◽  
Anne Kiil Berthelsen ◽  
Annika Loft ◽  
Peter de Nully Brown ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Hodgkin Lymphoma ◽  
Early Stage ◽  
Combined Modality Treatment ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Combined Modality

Combined-modality treatment of osteogenic sarcoma of the skull

1985 ◽  
Vol 63 (4) ◽  
pp. 562-567 ◽  
Author(s):  
Narayan Sundaresan ◽  
Andrew G. Huvos ◽  
Gerald Rosen ◽  
Joseph H. Galicich
Keyword(s):  
De Novo ◽  
Osteogenic Sarcoma ◽  
Surgical Excision ◽  
Combined Modality Treatment ◽  
Aggressive Approach ◽  
Content Type ◽  
Combined Modality ◽  
Additional Surgery ◽  
Long Term Survivors

✓ The authors present the results of combined-modality treatment in eight patients with osteosarcoma of the skull. Six patients had de novo tumors, and two others had secondary sarcomas resulting from malignant transformation in Paget's disease. Wide surgical excision and combination chemotherapy were used in seven patients, and surgery and radiation therapy were employed in one case. Following chemotherapy, six patients underwent additional surgery. This aggressive approach resulted in four long-term survivors among the patients with de novo tumors. These data suggest that surgery in combination with chemotherapy provides the best potential for long-term disease control in patients with osteosarcoma of the skull.

Sign in / Sign up

Export Citation Format

Share Document